Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Doses of the Glucokinase Activator Ly2608204 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2dm).

Trial Profile

Single Doses of the Glucokinase Activator Ly2608204 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2dm).

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2013

At a glance

  • Drugs LY 2608204 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 25 Mar 2013 New trial record
    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top